News Novartis’ $100m bet on eczema drug fails as MOR106 developme... Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in atopic dermatitis (also known as eczema).
News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK